Financial Times FT.com

Imclone addresses shortcomings of FLEX trial, development of KRAS biomarker to guide future patient selection

By Kimberly Ha and Elizabeth Krutoholow in New York

Published: May 23 2008 21:59 | Last updated: May 23 2008 21:59

Email options

The information entered on this page will not be used to send unsolicited email, and will not be sold to a 3rd party.Terms of use |Privacy policy

* required fields



(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)